References
- The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232
- Messerli F. H., Grossman E., Goldbourt U. Are beta‐blockers efficacious as first‐line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907
- Messerli F. H., Grossman E. Beta‐blockers and diuretics: To use or not to use. Am J Hypertens 1999; 12: 157S–163S
- Messerli F. H., Beevers D. G., Franklin S. S., Pickering T. G. Beta‐blockers in hypertension – The emperor has no clothes: An open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens 2003; 16: 870–873
- Mancia G., Grassi G., Zanchetti A. New‐onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
- Hansson L., Lindholm L. H., Niskanen L., Lanke J., Hedner T., Niklason A., , for the Captopril Prevention Project (CAPPP) study group, et al. Effect of angiotensin‐converting‐enzyme inhibitor compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616
- Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., , LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–1003
- Dahlöf B., Sever P. S., Poulter N. R., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895–906
- Lacourcière Y., Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27: 371–376
- Borghi C., Ambrosioni E. Zofenopril: A review of the evidence of its benefits in hypertension and acute myocardial infarction. Clin Drug Invest 2000; 20: 371–384
- Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press 2007; 16(Suppl)7–12
- Mallion J. ‐. M. An evaluation of the initial and long‐term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 Suppl: 13–18
- Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press 2007; 16(Suppl)19–24
- Turnbull F., Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527–1535
- Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., , Blood Pressure Lowering Treatment Trialists' Collaboration, et al. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005; 165: 1410–1419
- Malacco E., Castiglioni G., Corradi L., Cristofari M., Fogari R., Pisani A., et al. Dose–response relationship of zofenopril in essential hypertension: A 24‐hour blood pressure‐monitoring study. Clin Drug Invest 2002; 22: 9–15
- Zanchetti A., Parati G., Malacco E. Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension. Review article. Drugs 2006; 66: 1107–1115
- Lindholm L. H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta‐analysis. Lancet 2005; 366: 1545–1553
- Carlberg B., Samuelsson O., Lindholm L. H. Atenolol in hypertension: Is it a wise choice?. Lancet 2004; 1684–1689, 364